ITI Inc. (ITCI) announced that it has commenced a Phase 3 clinical trial, ITI-007-201, assessing lead product candidate ITI-007 for the treatment of agitation in patients with dementia, including Alzheimer's disease (AD). The primary endpoint is the treatment effect compared to placebo as measured by a 37-item scale called Cohen-Mansfield Agitation Inventory - Community version (CMAI-C) which measures the ability of a drug to reduce the overall frequency of agitation symptoms, including aggressive behaviors.